IAM1363 (HER2 TKI)
Iambic Therapeutics: company profile
Phase 1 registry
Company reports Phase 1/1b
Since , the date of the source that reports this phase.
Summary
IAM1363 is a HER2 TKI from Iambic Therapeutics. The source describes it as small molecule. It is being developed for HER2-altered cancers. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT06253871. The company reports Phase 1/1b. The AI role named in the source is molecule design. Registry records: NCT06253871, Phase 1, recruiting, updated Sep 9, 2026. About the company, based in United States: AI models coupled with automated chemistry and biology labs in a design-make-test loop; lead asset IAM1363 is a brain-penetrant HER2 inhibitor in Phase 1/1b. Antitumor activity, favorable safety at ESMO 2025. The latest dated source is from Oct 20, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Iambic Therapeutics
- Indication
- HER2-altered cancers
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1/1b, as of Oct 20, 2025
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
Antitumor activity, favorable safety at ESMO 2025
AI evidence
AI source: Company
“was first identified using Iambic's AI-driven drug discovery platform”
Trial records
- NCT06253871 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1/1b
Antitumor activity, favorable safety at ESMO 2025
-
NCT06253871 record updated
Phase 1, Recruiting
-
Registry check
Registry lists Phase 1 only; post said Phase 1/1b.
About Iambic Therapeutics
AI models coupled with automated chemistry and biology labs in a design-make-test loop; lead asset IAM1363 is a brain-penetrant HER2 inhibitor in Phase 1/1b.
Spot an error? Tell me and I'll fix it.